Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aude Flechon

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
BMC Cancer|August 7, 2014
Studying the impact of early life exposures to pesticides on the risk of testicular germ cell tumors during adulthood (TESTIS project): study protocolRémi Béranger, Olivia Pérol, Louis Bujan, et al.
The Lancet. Oncology|December 24, 2023
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 studyChristian Pfister, Gwenaelle Gravis, Aude Flechon, et al.
Pharmaceuticals (Basel, Switzerland)|July 29, 2023
Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal CarcinomaAnne Laure Giraudet, Armelle Vinceneux, Valentin Pretet, et al.
Bulletin Du Cancer|January 6, 2020
[Docetaxel for octogerian metastatic castration-resistant prostate cancer patient: A multicentric ten years' experience]Edouard Chanal, Amal Bousarsar, Alexis Vallard, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 8, 2025
Radiotherapy for penile cancers: 2025 updateGeneviève Loos, Alexandre Escande, Sabrina Aziez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancerJohann Sebastian de Bono, Joaquim Bellmunt, Gerhardt Attard, et al.
Pediatric Blood & Cancer|December 1, 2022
Extracranial germ cell tumours in children and adolescents: Results from the French TGM13 protocolCecile Faure-Conter, Daniel Orbach, Hélène Sudour-Bonnange, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2020
Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trialSylvie Negrier, Nathalie Rioux-Leclercq, Céline Ferlay, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2025
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trialAdrien Rousseau, Maryam Karimi, Stefan Michiels, et al.
Cancer Medicine|March 6, 2021
Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumorsChristine Chevreau, Christophe Massard, Aude Flechon, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
BMC Cancer|August 7, 2014
Studying the impact of early life exposures to pesticides on the risk of testicular germ cell tumors during adulthood (TESTIS project): study protocolRémi Béranger, Olivia Pérol, Louis Bujan, et al.
The Lancet. Oncology|December 24, 2023
Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 studyChristian Pfister, Gwenaelle Gravis, Aude Flechon, et al.
Pharmaceuticals (Basel, Switzerland)|July 29, 2023
Rationale for Prostate-Specific-Membrane-Antigen-Targeted Radionuclide Theranostic Applied to Metastatic Clear Cell Renal CarcinomaAnne Laure Giraudet, Armelle Vinceneux, Valentin Pretet, et al.
Bulletin Du Cancer|January 6, 2020
[Docetaxel for octogerian metastatic castration-resistant prostate cancer patient: A multicentric ten years' experience]Edouard Chanal, Amal Bousarsar, Alexis Vallard, et al.
Cancer Radiotherapie : Journal De La Societe Francaise De Radiotherapie Oncologique|November 8, 2025
Radiotherapy for penile cancers: 2025 updateGeneviève Loos, Alexandre Escande, Sabrina Aziez, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 20, 2007
Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancerJohann Sebastian de Bono, Joaquim Bellmunt, Gerhardt Attard, et al.
Pediatric Blood & Cancer|December 1, 2022
Extracranial germ cell tumours in children and adolescents: Results from the French TGM13 protocolCecile Faure-Conter, Daniel Orbach, Hélène Sudour-Bonnange, et al.
European Journal of Cancer (Oxford, England : 1990)|March 9, 2020
Axitinib in first-line for patients with metastatic papillary renal cell carcinoma: Results of the multicentre, open-label, single-arm, phase II AXIPAP trialSylvie Negrier, Nathalie Rioux-Leclercq, Céline Ferlay, et al.
European Journal of Cancer (Oxford, England : 1990)|October 4, 2025
Adjusting for abiraterone-prednisone cross-over in de novo metastatic castration-sensitive prostate cancer: a post-hoc analysis of the PEACE-1 trialAdrien Rousseau, Maryam Karimi, Stefan Michiels, et al.
Cancer Medicine|March 6, 2021
Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumorsChristine Chevreau, Christophe Massard, Aude Flechon, et al.
Pageof 5